Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RLRelmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD)

NASDAQ · Currency in USD
$3.27 ▼ -0.02 (-0.61%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.27 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.29
Open
$3.26
Day's Range
$3.18 – $3.34
52 Week Range
$2.15 – $8.00
Volume
1,100,741
Avg. Volume
1,639,327
Market Cap
$348.81M
Beta (5Y Monthly)
0.45
PE Ratio (TTM)
--
EPS (TTM)
-$0.55
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Relmada Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Sergio Traversa

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.14
DateEst.Actual
Aug 6, 2026-$0.20-$0.11Beat
May 12, 2026-$0.18-$0.22Miss
Mar 19, 2026-$0.14-$0.27Miss
Nov 13, 2025-$0.04-$0.30Miss
Aug 7, 2025-$0.25-$0.30Miss
May 12, 2025-$0.31-$0.58Miss

Analyst view

Consensus price target
$12.00 ▲ +267.0%
Range $12.00 – $12.00
Rating: Buy
Buy 63% · Hold 25% · Sell 13%

Get free alerts on RLMD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.